In vitro activity of CEM-101, a new fluoroketolide antibiotic, against Chlamydia trachomatis and Chlamydia (Chlamydophila) pneumoniae

Patricia M Roblin; Stephan A Kohlhoff; Charles Parker; Margaret R Hammerschlag

doi:10.1128/AAC.01343-09

In vitro activity of CEM-101, a new fluoroketolide antibiotic, against Chlamydia trachomatis and Chlamydia (Chlamydophila) pneumoniae

Antimicrob Agents Chemother. 2010 Mar;54(3):1358-9. doi: 10.1128/AAC.01343-09. Epub 2009 Dec 28.

Authors

Patricia M Roblin¹, Stephan A Kohlhoff, Charles Parker, Margaret R Hammerschlag

Affiliation

¹ Division of Infectious Diseases, Department of Pediatrics, State University of New York Downstate Medical Center, Brooklyn, New York 11203-2098, USA.

Abstract

The in vitro activities of CEM-101, telithromycin, azithromycin, clarithromycin, and doxycycline against 10 isolates each of Chlamydia trachomatis and Chlamydia (Chlamydophila) pneumoniae were tested. The MIC at which 90% of the isolates of both C. trachomatis and C. pneumoniae were inhibited and the minimal bactericidal concentration at which 90% of the isolates were killed by CEM-101 were 0.25 microg/ml (ranges, 0.125 to 0.5 microg/ml for C. trachomatis and 0.25 to 1.0 microg/ml for C. pneumoniae).

MeSH terms

Adult
Anti-Bacterial Agents / pharmacology*
Child
Child, Preschool
Chlamydia Infections / microbiology
Chlamydia trachomatis / drug effects*
Chlamydia trachomatis / isolation & purification
Chlamydophila Infections / microbiology
Chlamydophila pneumoniae / drug effects*
Chlamydophila pneumoniae / isolation & purification
Female
Humans
Infant
Macrolides / pharmacology*
Microbial Sensitivity Tests
Pneumonia, Bacterial / microbiology
Triazoles / pharmacology*

Substances

Anti-Bacterial Agents
Macrolides
Triazoles
solithromycin